These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 37099027)

  • 21. Managing Waldenström's macroglobulinemia with BTK inhibitors.
    Buske C; Jurczak W; Salem JE; Dimopoulos MA
    Leukemia; 2023 Jan; 37(1):35-46. PubMed ID: 36402930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current therapy guidelines for Waldenstrom's macroglobulinaemia.
    Kastritis E; Dimopoulos MA
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):194-205. PubMed ID: 27825466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia.
    Varettoni M; Matous JV
    Hematol Oncol Clin North Am; 2023 Aug; 37(4):707-717. PubMed ID: 37246088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Waldenström's macroglobulinemia].
    Watanabe R
    Rinsho Ketsueki; 2015 Oct; 56(10):2074-85. PubMed ID: 26458447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
    Gertz MA
    Am J Hematol; 2023 Feb; 98(2):348-358. PubMed ID: 36588395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
    Dimopoulos MA; Gertz MA; Kastritis E; Garcia-Sanz R; Kimby EK; Leblond V; Fermand JP; Merlini G; Morel P; Morra E; Ocio EM; Owen R; Ghobrial IM; Seymour J; Kyle RA; Treon SP
    J Clin Oncol; 2009 Jan; 27(1):120-6. PubMed ID: 19047284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How I treat Waldenström macroglobulinemia.
    Treon SP
    Blood; 2015 Aug; 126(6):721-32. PubMed ID: 26002963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current and novel BTK inhibitors in Waldenström's macroglobulinemia.
    Ntanasis-Stathopoulos I; Gavriatopoulou M; Fotiou D; Dimopoulos MA
    Ther Adv Hematol; 2021; 12():2040620721989586. PubMed ID: 33613931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
    Dimopoulos MA; Kastritis E; Owen RG; Kyle RA; Landgren O; Morra E; Leleu X; García-Sanz R; Munshi N; Anderson KC; Terpos E; Ghobrial IM; Morel P; Maloney D; Rummel M; Leblond V; Advani RH; Gertz MA; Kyriakou C; Thomas SK; Barlogie B; Gregory SA; Kimby E; Merlini G; Treon SP
    Blood; 2014 Aug; 124(9):1404-11. PubMed ID: 25027391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ibrutinib in previously treated Waldenström's macroglobulinemia.
    Treon SP; Tripsas CK; Meid K; Warren D; Varma G; Green R; Argyropoulos KV; Yang G; Cao Y; Xu L; Patterson CJ; Rodig S; Zehnder JL; Aster JC; Harris NL; Kanan S; Ghobrial I; Castillo JJ; Laubach JP; Hunter ZR; Salman Z; Li J; Cheng M; Clow F; Graef T; Palomba ML; Advani RH
    N Engl J Med; 2015 Apr; 372(15):1430-40. PubMed ID: 25853747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bing-Neel Syndrome: An Initial Manifestation of Waldenstrom Macroglobulinemia.
    Lee MS; Sathe S; Valasapalli S; Grosse Perdekamp M
    Cureus; 2021 Nov; 13(11):e19402. PubMed ID: 34926004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
    Paludo J; Abeykoon JP; Shreders A; Ansell SM; Kumar S; Ailawadhi S; King RL; Koehler AB; Reeder CB; Buadi FK; Dispenzieri A; Lacy MQ; Dingli D; Witzig TE; Go RS; Gonsalves WI; Kourelis T; Warsame R; Leung N; Habermann TM; Hayman S; Lin Y; Kyle RA; Rajkumar SV; Gertz MA; Kapoor P
    Ann Hematol; 2018 Aug; 97(8):1417-1425. PubMed ID: 29610969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Waldenstrom's macroglobulinemia in the era of immunotherapy.
    Vaxman I; Gertz M
    Leuk Lymphoma; 2020 Jun; 61(6):1292-1304. PubMed ID: 31960730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Future Directions in the Frontline Management of Waldenström Macroglobulinemia.
    Buske C; Palomba ML
    Hematol Oncol Clin North Am; 2023 Aug; 37(4):719-725. PubMed ID: 37270384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
    Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current options to manage Waldenström's macroglobulinemia.
    Benevolo G; Nicolosi M; Santambrogio E; Vitolo U
    Expert Rev Hematol; 2017 Jul; 10(7):637-647. PubMed ID: 28592170
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia.
    Treon SP; Tripsas CK; Meid K; Kanan S; Sheehy P; Chuma S; Xu L; Cao Y; Yang G; Liu X; Patterson CJ; Warren D; Hunter ZR; Turnbull B; Ghobrial IM; Castillo JJ
    Blood; 2014 Jul; 124(4):503-10. PubMed ID: 24859363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia.
    Castillo JJ; Advani RH; Branagan AR; Buske C; Dimopoulos MA; D'Sa S; Kersten MJ; Leblond V; Minnema MC; Owen RG; Palomba ML; Talaulikar D; Tedeschi A; Trotman J; Varettoni M; Vos JM; Treon SP; Kastritis E
    Lancet Haematol; 2020 Nov; 7(11):e827-e837. PubMed ID: 33091356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
    Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
    Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia.
    Gavriatopoulou M; Fotiou D; Ntanasis-Stathopoulos I; Dimopoulos MA
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):663-674. PubMed ID: 32631091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.